

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF  
03 AUG 14

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ropes & Gray			
2. Address <input type="checkbox"/> Check if different than previously reported 1301 K St. NW, Suite 800 East			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20005			
4. Contact Name Thomas M. Susman	Telephone (202) 626-3920	E-mail (optional) tsusman@ropesgray.com	5. Senate ID # 3368
7. Client Name <input type="checkbox"/> Self Johnson & Johnson/Ortho Biotech			6. House ID # 3071

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date \_\_\_\_\_

11. No Lobbyin

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this re period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,</p> <p><b>14. REPORTING METHOD.</b> Check box to indica accounting method. See instructions for description c</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA defin</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 60 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 16 Internal Revenue Code</p>
---	--

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

LD-2 (REV. 6/98)

Registrant Name Ropes & Gray Client Name Johnson & Johnson/Ortho Biotech

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide the information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer therapies.  
H.R. 1288; S. 1037

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sam Turner, Partner	
Elizabeth Goss, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_ Date 8/06/03

Printed Name and Title Thomas M. Susman, Partner

Form LD-2 (Rev.6/98)

Page .

Registrant Name Ropes & Gray Client Name Johnson & Johnson/Ortho Biotech

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Legislative issues involving potential changes to the Federal Food, Drug & Cosmetic Act.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

U.S. House of Representatives  
U.S. Senate  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Alan R. Bennett, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date 8/06/03

